Differentiating therapeutic procedures according to gender is not a common practice, in spite of the fact that scientists have been observing some related to gender (and also to age) differences in incidence of particular types of cancer. Incidence of malicious glioblastoma is about twice as high in case of men.

In the January’19 edition of Science Translational Medicine journal there were published some results of the research on molecular characteristics of malicious glioblastoma related to gender. It was shown that in GBM tumors the differences do appear and could be useful in the process of taking therapeutic decisions.

One of the observed differences was specific IDH1 mutation. There was observed that almost all muted female tumors were correlated to fc3 and that meant better prognosis.

Also a better reaction of tumor to standard TMZ treatment was observed in case of female tumors.